Free tool
FAERS Monitor: Spiriva Respimat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021936 or its brand name (Spiriva Respimat, Tiotropium Bromide). Reports on generic versions are filed under their own applications.
Reports
11,487
Serious
6,855
60% of reports
Hospitalization
3,719
Death reported
778
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea2,340
- asthma1,510
- cough1,093
- pneumonia934
- wheezing846
- drug ineffective771
- off label use716
- therapeutic product effect incomplete581
- chronic obstructive pulmonary disease570
- loss of personal independence in daily activities520
- fatigue508
- headache469
- sleep disorder due to a general medical condition444
- death425
- malaise412
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 13 |
| 2011 | 24 |
| 2012 | 42 |
| 2013 | 75 |
| 2014 | 31 |
| 2015 | 50 |
| 2016 | 121 |
| 2017 | 418 |
| 2018 | 1,080 |
| 2019 | 1,223 |
| 2020 | 1,652 |
| 2021 | 1,213 |
| 2022 | 1,006 |
| 2023 | 1,000 |
| 2024 | 1,273 |
| 2025 | 1,209 |
| 2026 | 1,051 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,672 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sleep disorder due to a general medical conditionSignal | 444 | 49.1 | 44.8 | 20,356 |
| wheezingSignal | 846 | 26.5 | 24.8 | 20,483 |
| asthmaSignal | 1,510 | 24.8 | 23.6 | 34,162 |
| chronic obstructive pulmonary diseaseSignal | 570 | 20.2 | 18.6 | 10,302 |
| loss of personal independence in daily activitiesSignal | 520 | 20.0 | 18.4 | 9,301 |
| therapeutic product effect incompleteSignal | 581 | 15.1 | 13.9 | 7,581 |
| dyspnoeaSignal | 2,340 | 7.6 | 7.3 | 13,710 |
| coughSignal | 1,093 | 7.2 | 6.8 | 5,842 |
| pneumoniaSignal | 934 | 5.3 | 5.0 | 3,291 |
| malaise | 412 | 1.7 | 1.6 | 126 |
| off label use | 716 | 1.5 | 1.4 | 123 |
| headache | 469 | 1.4 | 1.3 | 48 |
| fatigue | 508 | 1.2 | 1.1 | 17 |
| drug ineffective | 771 | 1.1 | 1.0 | 4 |
| death | 425 | 0.9 | 0.8 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.